|
|
||||||||






,
,
* Section of Rheumatology, Department of Medicine, and Departments of
Immunology/Microbiology and
Orthopedic Surgery and Biochemistry, Rush Presbyterian-St. Lukes Medical Center, Chicago, IL 60612;
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115; and
¶ Klinische Forschergruppe fur Rheumatologie, Freiburg, Germany
IL-4, a well-recognized modulator of macrophage activation, is
perceived as an anti-inflammatory cytokine; however, under certain
circumstances IL-4 may function as a proinflammatory cytokine. We have
previously demonstrated that IL-4 treatment of mice with
proteoglycan-induced arthritis (PGIA) inhibited the development of
disease. To determine whether the capacity of IL-4 to inhibit disease
is dependent on IL-4-mediated regulation of IL-12, we assessed the
requirement for IL-4 in modulating development of PGIA. Immunization of
mice, lacking IL-4 and Stat6, with proteoglycan results in a
significant increase in arthritis severity in comparison to wild-type
controls, suggesting that arthritis severity is regulated by IL-4
through a Stat6-dependent mechanism. Concomitant with exacerbated
disease in IL-4-/- mice, there is a significant increase
in the systemic production of proinflammatory cytokines IL-12, TNF-
,
and IFN-
and in levels of mRNA transcripts for proinflammatory
cytokines and chemokines in joints. Disease is suppressed in
Stat4-/- mice indicating that elevated levels of IL-12
contribute to exacerbation of arthritis and that suppression is
accompanied by reduced levels of IFN-
production. In support of
this, IFN-
-/- mice are protected from PGIA and the
degree of inflammation is similar to Stat4-/- mice. The
decrease in disease severity in IFN-
-/- and
Stat4-/- mice correlates with diminished TNF-
levels
but there is no switch to a Th2-type response. Taken together, these
results suggest that IL-4 regulates the severity of disease in PGIA by
controlling IL-12 production, which in turn regulates the magnitude of
IFN-
expression through a Stat4-dependent
pathway.
This article has been cited by other articles:
![]() |
H. Li, Q. Zou, Z. Xie, Y. Liu, B. Zhong, S. Yang, P. Zheng, F. Yang, Y. Fang, and Y. Wu A haplotype in STAT4 gene associated with rheumatoid arthritis in Caucasians is not associated in the Han Chinese population, but with the presence of rheumatoid factor Rheumatology, November 1, 2009; 48(11): 1363 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Rosenzweig, T. Kawaguchi, T. M. Martin, S. R. Planck, M. P. Davey, and J. T. Rosenbaum Nucleotide Oligomerization Domain-2 (NOD2)-Induced Uveitis: Dependence on IFN-{gamma} Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1739 - 1745. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Rosenzweig, M. M. Jann, T. T. Glant, T. M. Martin, S. R. Planck, W. van Eden, P. J. S. van Kooten, R. A. Flavell, K. S. Kobayashi, J. T. Rosenbaum, et al. Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis J. Leukoc. Biol., April 1, 2009; 85(4): 711 - 718. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sasaki, X. Zhao, A. D. Pardee, R. Ueda, M. Fujita, S. Sehra, M. H. Kaplan, L. P. Kane, H. Okada, and W. J. Storkus Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo J. Immunol., July 1, 2008; 181(1): 104 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Doodes, Y. Cao, K. M. Hamel, Y. Wang, B. Farkas, Y. Iwakura, and A. Finnegan Development of Proteoglycan-Induced Arthritis Is Independent of IL-17 J. Immunol., July 1, 2008; 181(1): 329 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Huber, E. M. Jacobson, K. Jazdzewski, E. S. Concepcion, and Y. Tomer Interleukin (IL)-23 Receptor Is a Major Susceptibility Gene for Graves' Ophthalmopathy: The IL-23/T-helper 17 Axis Extends to Thyroid Autoimmunity J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1077 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Cao, P. D. Doodes, T. T. Glant, and A. Finnegan IL-27 Induces a Th1 Immune Response and Susceptibility to Experimental Arthritis J. Immunol., January 15, 2008; 180(2): 922 - 930. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cortes, M. Perez-G, M. D. Rivas, and J. Zamorano Kaempferol Inhibits IL-4-Induced STAT6 Activation by Specifically Targeting JAK3 J. Immunol., September 15, 2007; 179(6): 3881 - 3887. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. F. Remmers, R. M. Plenge, A. T. Lee, R. R. Graham, G. Hom, T. W. Behrens, P. I.W. de Bakker, J. M. Le, H.-S. Lee, F. Batliwalla, et al. STAT4 and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus N. Engl. J. Med., September 6, 2007; 357(10): 977 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Hildner, P. Schirmacher, I. Atreya, M. Dittmayer, B. Bartsch, P. R. Galle, S. Wirtz, and M. F. Neurath Targeting of the Transcription Factor STAT4 by Antisense Phosphorothioate Oligonucleotides Suppresses Collagen-Induced Arthritis J. Immunol., March 15, 2007; 178(6): 3427 - 3436. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhou, W. Tang, Y.-X. Ren, P.-L. He, F. Zhang, L.-P. Shi, Y.-F. Fu, Y.-C. Li, S. Ono, H. Fujiwara, et al. (5R)-5-Hydroxytriptolide Attenuated Collagen-Induced Arthritis in DBA/1 Mice via Suppressing Interferon-{gamma} Production and Its Related Signaling J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 35 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
J G Walker, M J Ahern, M Coleman, H Weedon, V Papangelis, D Beroukas, P J Roberts-Thomson, and M D Smith Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis Ann Rheum Dis, February 1, 2006; 65(2): 149 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pace, C. Pioli, and G. Doria IL-4 Modulation of CD4+CD25+ T Regulatory Cell-Mediated Suppression J. Immunol., June 15, 2005; 174(12): 7645 - 7653. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. O'Neill, M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan Antigen-Specific B Cells Are Required as APCs and Autoantibody-Producing Cells for Induction of Severe Autoimmune Arthritis J. Immunol., March 15, 2005; 174(6): 3781 - 3788. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zamorano, M. D. Rivas, F. Setien, and M. Perez-G Proteolytic Regulation of Activated STAT6 by Calpains J. Immunol., March 1, 2005; 174(5): 2843 - 2848. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Bunting, W.-M. Yu, H. L. Bradley, E. Haviernikova, A. E. Kelly-Welch, A. D. Keegan, and C.-K. Qu Increased numbers of committed myeloid progenitors but not primitive hematopoietic stem/progenitors in mice lacking STAT6 expression J. Leukoc. Biol., August 1, 2004; 76(2): 484 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zamorano, M. D. Rivas, A. Garcia-Trinidad, C.-K. Qu, and A. D. Keegan Phosphatidylcholine-Specific Phospholipase C Activity Is Necessary for the Activation of STAT6 J. Immunol., October 15, 2003; 171(8): 4203 - 4209. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |